OBSV Stock Overview
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.02|
|52 Week High||US$5.55|
|52 Week Low||US$1.93|
|1 Month Change||-19.52%|
|3 Month Change||-36.08%|
|1 Year Change||-6.05%|
|3 Year Change||-86.13%|
|5 Year Change||n/a|
|Change since IPO||-82.66%|
Recent News & Updates
|OBSV||US Biotechs||US Market|
Return vs Industry: OBSV underperformed the US Biotechs industry which returned -1.4% over the past year.
Return vs Market: OBSV underperformed the US Market which returned 16.6% over the past year.
|OBSV Average Weekly Movement||6.8%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||14.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: OBSV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: OBSV's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization.
ObsEva Fundamentals Summary
|OBSV fundamental statistics|
Is OBSV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OBSV income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.76|
|Net Profit Margin||-227.52%|
How did OBSV perform over the long term?See historical performance and comparison
Is ObsEva undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OBSV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OBSV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OBSV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: OBSV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OBSV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OBSV is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.6x).
How is ObsEva forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OBSV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OBSV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OBSV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OBSV's revenue is expected to decline over the next 3 years (-98.1% per year).
High Growth Revenue: OBSV's revenue is forecast to decline over the next 3 years (-98.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OBSV's Return on Equity is forecast to be high in 3 years time
How has ObsEva performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OBSV is currently unprofitable.
Growing Profit Margin: OBSV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OBSV is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare OBSV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OBSV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: OBSV has a negative Return on Equity (-128.78%), as it is currently unprofitable.
How is ObsEva's financial position?
Financial Position Analysis
Short Term Liabilities: OBSV's short term assets ($72.1M) exceed its short term liabilities ($18.8M).
Long Term Liabilities: OBSV's short term assets ($72.1M) exceed its long term liabilities ($34.7M).
Debt to Equity History and Analysis
Debt Level: OBSV has more cash than its total debt.
Reducing Debt: Insufficient data to determine if OBSV's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OBSV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OBSV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17% each year
What is ObsEva current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OBSV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OBSV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OBSV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OBSV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OBSV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brian O'Callaghan (52 yo)
Mr. Brian O'Callaghan has been Director at Bolt Biotherapeutics, Inc. since November 2021. Mr. O'Callaghan serves as Chief Executive Officer of ObsEva SA since December 1, 2020 and serves as its Director s...
CEO Compensation Analysis
Compensation vs Market: Brian's total compensation ($USD4.29M) is above average for companies of similar size in the US market ($USD1.15M).
Compensation vs Earnings: Insufficient data to compare Brian's compensation with company performance.
Experienced Management: OBSV's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: OBSV's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.7%.
ObsEva SA's employee growth, exchange listings and data sources
- Name: ObsEva SA
- Ticker: OBSV
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$150.344m
- Shares outstanding: 74.43m
- Website: https://www.obseva.com
Number of Employees
- ObsEva SA
- Chemin des Aulx, 12
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/04 00:14|
|End of Day Share Price||2021/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.